A. H. Ayesha Lavell

A. H. Ayesha Lavell

Auto-generated profile, based on publicly available information

A. H. Ayesha Lavell

Department of Internal Medicine Amsterdam UMC Location Vrije Universiteit Amsterdam Amsterdam The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
TCTom G. Caniels
Tom G. Caniels
IBIlja Bontjer
Ilja Bontjer
KSKarlijn van der Straten
Karlijn van der Straten
MPMeliawati Poniman
Meliawati Poniman
JBJudith A. Burger
Judith A. Burger
RSRogier W. Sanders
Rogier W. Sanders
Antibodies of convalescent COVID-19 patients and vaccine recipients show reduced recognition of SARS-CoV-2 variants of concern.

17 May 2022 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
MGMarit van Gils
Marit van Gils
ALAyesha Lavell
Ayesha Lavell
KSKarlijn van der Straten
Karlijn van der Straten
BABrent Appelman
Brent Appelman
IBIlja Bontjer
Ilja Bontjer
RSRogier W. Sanders
Rogier W. Sanders
Background: Emerging and future SARS-CoV-2 variants may jeopardize the effectiveness of vaccination campaigns. Therefore, it is important to know how the different vaccines perform against diverse SARS-CoV-2 variants. Methods and findings: In a prospective cohort of 165 SARS-CoV-2 naive health care workers in the Netherlands, vaccinated with either one of four vaccines (BNT162b2, mRNA-1273, AZD1222 or Ad26.COV2.S), we performed a head-to-head comparison of the ability of sera to recognize and neutralize SARS-CoV-2 variants of concern (VOCs; Alpha, Beta, Gamma, Delta and Omicron). Repeated serum sampling was performed 5 times during a year (from January 2021 till January 2022), including before and after booster vaccination with BNT162b2. Four weeks after completing the initial vaccination series, SARS-CoV-2 wild-type neutralizing antibody titers were highest in recipients of mRNA-1273, followed by recipients of BNT162b2 (geometric mean titers (GMT) of 358 [95% CI 231–556] and 214 [95% CI 153–299], respectively; p<0.05), and substantially lower in those vaccinated with the adenovirus vector-based vaccines AZD1222 and Ad26.COV2.S (GMT of 18 [95% CI 11–30] and 14 [95% CI 8–25] IU/ml, respectively; p<0.001). VOCs neutralization was reduced in all vaccine groups, with the greatest reduction in neutralization GMT observed against the Omicron variant (fold change 0.03 [95% CI 0.02–0.04], p<0.001). The booster BNT162b2 vaccination increased neutralizing antibody titers for all groups with substantial improvement against the VOCs including the Omicron variant. We used linear regression and linear mixed model analysis. All results were adjusted for possible confounding of age and sex. Study limitations include the lack of cellular immunity data. Conclusions: Overall, this study shows that the mRNA vaccines appear superior to adenovirus vector-based vaccines in inducing neutralizing antibodies against VOCs four weeks after initial vaccination and after booster vaccination, which implies the use of mRNA vaccines for both initial and booster vaccination.

24 September 2021 in EBioMedicine
Verified
Journal Article
Open access
BABrent Appelman
Brent Appelman
KSKarlijn van der Straten
Karlijn van der Straten
ALA.H. Ayesha Lavell
A.H. Ayesha Lavell
MSMichiel Schinkel
Michiel Schinkel
MSMarleen A. Slim
Marleen A. Slim
AVAlexander Pj Vlaar
Alexander Pj Vlaar
To optimise the use of available SARS-CoV-2 vaccines, some advocate delaying second vaccination for individuals infected within six months. We studied whether post-vaccination immune response is equally potent in individuals infected over six months prior to vaccination. We tested serum IgG binding to SARS-CoV-2 spike protein and neutralising capacity in 110 healthcare workers, before and after both BNT162b2 messenger RNA (mRNA) vaccinations. We compared outcomes between participants with more recent infection (n = 18, median two months, IQR 2-3), with infection-vaccination interval over six months (n = 19, median nine months, IQR 9-10), and to those not previously infected (n = 73). Both recently and earlier infected participants showed comparable humoral immune responses after a single mRNA vaccination, while exceeding those of previously uninfected persons after two vaccinations with 2.5 fold (p = 0.003) and 3.4 fold (p < 0.001) for binding antibody levels, and 6.4 and 7.2 fold for neutralisation titres, respectively (both p < 0.001). The second vaccine dose yielded no further substantial improvement of the humoral response in the previously infected participants (0.97 fold, p = 0.92), while it was associated with a 4 fold increase in antibody binding levels and 18 fold increase in neutralisation titres in previously uninfected participants (both p < 0.001). Adjustment for potential confounding of sex and age did not affect these findings. Delaying the second vaccination in individuals infected up to ten months prior may constitute a more efficient use of limited vaccine supplies. Netherlands Organization for Health Research and Development ZonMw; Corona Research Fund Amsterdam UMC; Bill & Melinda Gates Foundation.

11 June 2025 in PLOS Mental Health
Verified
Journal Article
Open access
PDF file
ALA Lavell
A Lavell
JSJonne Sikkens
Jonne Sikkens
DBDavid Buis
David Buis
YSYvo Smulders
Yvo Smulders
CVChristiaan Vinkers
Christiaan Vinkers
JTJoeri Tijdink
Joeri Tijdink
Health care workers (HCWs) faced more stressors during the COVID-19 pandemic, potentially increasing depression, anxiety and post-traumatic stress disorder (PTSD). Insight into mental health dynamics and determinants in HCWs during the pandemic could help to maintain and improve mental health and resilience in future pandemics. In this longitudinal cohort study, HCWs received five surveys from November 2020 to March 2023 assessing self-reported symptoms of depression (PHQ-9), anxiety (GAD-7), PTSD (PCL-5), stress (PSS), burn-out (UBOS-EE), insomnia (ISI), resilience (RS) and work engagement (UWES). In addition to the longitudinal analysis, mental health symptoms were assessed in relation to possible predictors, e.g. patient care roles or prior SARS-CoV-2 infection. A total of 384 HCWs (95% of HCWs given consent) completed at least one survey, 326 (81%) completed two or more. Mental health significantly declined in December 2021 compared to November 2020, with mean increases of 1.16 (95% CI 0.73 to 1.58, d = 0.48), 0.79 (95% CI 0.41 to 1.17, d = 0.37) and 1.96 (95% CI 0.95 to 2.97, d = 0.35) on the PHQ-9 (range 0–27), GAD-7 (range 0–21) and PCL-5 (range 0–80), respectively, with similar results in multivariable analysis. Symptoms returned to November 2020 levels in March 2023. No differences were found regarding patient care roles, prior SARS-CoV-2 infection, years of work experience, or hospital workdays per week. Mental health significantly declined during the COVID-19 pandemic, after which mental health symptoms returned to baseline as the burden of COVID-19 patients decreased and public measures were lifted. This demonstrates this population’s ability to successfully adapt to challenging experiences and emphasizes the need for support strategies tailored to the critical phases of any future healthcare crises.

9 January 2024 in Viruses
Verified
Journal Article
Open access
PDF file
ATAnne Timmerman
Anne Timmerman
LCLisanne Commandeur
Lisanne Commandeur
MDMartin Deijs
Martin Deijs
MBMaarten G. J. M. Burggraaff
Maarten G. J. M. Burggraaff
ALA. H. Ayesha Lavell
A. H. Ayesha Lavell
LHLia Van der Hoek
Lia Van der Hoek
Members of the Anelloviridae family dominate the blood virome, emerging early in life. The anellome, representing the variety of anelloviruses within an individual, stabilizes by adulthood. Despite their supposedly commensal nature, elevated anellovirus concentrations under immunosuppressive treatment indicate an equilibrium controlled by immunity. Here, we investigated whether anelloviruses are sensitive to the immune activation that accompanies a secondary infection. As a model, we investigated 19 health care workers (HCWs) with initial SARS-CoV-2 infection, with blood sampling performed pre and post infection every 4 weeks in a 3-month-follow-up during the early 2020 COVID-19 pandemic. A concurrently followed control group (n = 27) remained SARS-CoV-2-negative. Serum anellovirus loads were measured using qPCR. A significant decrease in anellovirus load was found in the first weeks after SARS-CoV-2 infection, whereas anellovirus concentrations remained stable in the uninfected control group. A restored anellovirus load was seen approximately 10 weeks after SARS-CoV-2 infection. For five subjects, an in-time anellome analysis via Illumina sequencing could be performed. In three of the five HCWs, the anellome visibly changed during SARS-CoV-2 infection and returned to baseline in two of these cases. In conclusion, anellovirus loads in blood can temporarily decrease upon an acute secondary infection.

27 September 2023 in Vaccine
Verified
Journal Article
Open access
ASA.E. Schramade
A.E. Schramade
KSK. van der Straten
K. van der Straten
KDK.A. van Dort
K.A. van Dort
NKNeeltje Kootstra
Neeltje Kootstra
MGM.J. van Gils
M.J. van Gils
WWW. Joost Wiersinga
W. Joost Wiersinga
To improve effectiveness of vaccination against SARS-CoV-2, it is important to identify factors that influence the immune response induced by vaccination. Evidence for the role of vitamin D in immune response against SARS-CoV-2 is contradictory. It is therefore of interest whether 25-hydroxyvitamin D (25[OH]D) concentrations affect the humoral and/or cellular response following SARS-CoV-2 vaccination. In this prospective cohort study, blood samples were collected from 98 SARS-CoV-2 naive health care workers (HCW) receiving the first two doses of either BNT162b2 or mRNA-1273 in 2021. Wild-type spike (S) protein binding and neutralizing antibodies were determined approximately three weeks after the first dose and four to five weeks after the second dose. Antigen specific T-cells and functionality (proliferative response and interferon gamma [IFN-γ] release) were determined in 18 participants four weeks after the second dose of BNT162b2. We studied the association between 25(OH)D concentrations, which were determined prior to vaccination, and humoral and cellular immune responses following vaccination. We found no association between 25(OH)D concentrations (median 55.9 nmol/L [IQR 40.5-69.8]) and binding or neutralizing antibody titers after complete vaccination (fold change of antibody titers per 10 nmol/L 25(OH)D increase: 0.98 [95% CI 0.93-1.04] and 1.03 [95% CI: 0.96-1.11], respectively), adjusted for age, sex and type of mRNA vaccine. Subsequently, continuous 25(OH)D concentrations were divided into commonly used clinical categories (<25 nmol/L [n = 6, 6%], 25-49 nmol/L [n = 33, 34%], 50-75 nmol/L [n = 37, 38%] and ≥75 nmol/L [n = 22, 22%]), but no association with the humoral immune response following vaccination was found. Also, 25(OH)D concentrations were not associated with the SARS-CoV-2 specific T cell response. No association was found between 25(OH)D concentrations and the humoral or cellular immune response following mRNA vaccination against SARS-CoV-2. Based on our findings there is no rationale to advise vitamin D optimization preceding SARS-CoV-2 vaccination in HCW with moderate vitamin D status.